These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 30903743)
1. Chip-based digital polymerase chain reaction technology is useful for monitoring the JAK2 V617F allele burden in Philadelphia-negative myeloproliferative neoplasms. Furuya D; Moriai M; Murai R; Moriai R; Koizumi Y; Endo T; Asanuma K; Yanagihara N; Takahashi S Int J Lab Hematol; 2019 Oct; 41(5):e113-e116. PubMed ID: 30903743 [No Abstract] [Full Text] [Related]
2. Improved diagnosis of the transition to JAK2 (V⁶¹⁷F) homozygosity: the key feature for predicting the evolution of myeloproliferative neoplasms. Gonzalez MS; De Brasi CD; Bianchini M; Gargallo P; Stanganelli C; Zalcberg I; Larripa IB PLoS One; 2014; 9(1):e86401. PubMed ID: 24475114 [TBL] [Abstract][Full Text] [Related]
3. A new allelic discrimination assay using locked nucleic acid-modified nucleotides (LNA) probes for detection of JAK2 V617F mutation. Marková J; Průková D; Volková Z; Schwarz J Leuk Lymphoma; 2007 Mar; 48(3):636-9. PubMed ID: 17454614 [No Abstract] [Full Text] [Related]
4. Thrombin generation - a potentially useful biomarker of thrombotic risk in Philadelphia-negative myeloproliferative neoplasms. Mihaila RG Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2017 Mar; 161(1):50-53. PubMed ID: 28145534 [TBL] [Abstract][Full Text] [Related]
5. Atypical chronic myeloid leukemia as defined in the WHO classification is a JAK2 V617F negative neoplasm. Fend F; Horn T; Koch I; Vela T; Orazi A Leuk Res; 2008 Dec; 32(12):1931-5. PubMed ID: 18555525 [TBL] [Abstract][Full Text] [Related]
6. Isolated thrombocytosis as first sign of chronic myeloid leukemia with e6a2 BCR/ABL fusion transcript, JAK2 negativity and complete response to imatinib. Breccia M; Cannella L; Diverio D; Streponi P; Nanni M; Stefanizzi C; Natalino F; Mecarocci S; Alimena G Leuk Res; 2008 Jan; 32(1):177-80. PubMed ID: 17688946 [TBL] [Abstract][Full Text] [Related]
7. The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms. Borowczyk M; Wojtaszewska M; Lewandowski K; Gil L; Lewandowska M; Lehmann-Kopydłowska A; Kroll-Balcerzak R; Balcerzak A; Iwoła M; Michalak M; Komarnicki M Thromb Res; 2015 Feb; 135(2):272-80. PubMed ID: 25559461 [TBL] [Abstract][Full Text] [Related]
8. [The investigation of JAK2 V617F point mutation in myeloproliferative disorders by allele-specific polymerase chain reaction in combination with sequence analysis]. Zhang SJ; Li WD; Song JH; Xu W; Qiu HX; Li JY Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(30):2109-12. PubMed ID: 17988529 [TBL] [Abstract][Full Text] [Related]
9. Association of TNF polymorphisms with JAK2 (V617F) myeloproliferative neoplasms in Brazilian patients. Macedo LC; de Cesare Quintero F; Pagliari-E-Silva S; Pagnano KB; Rodrigues C; de Alencar JB; Sell AM; Visentainer JE Blood Cells Mol Dis; 2016 Mar; 57():54-7. PubMed ID: 26852656 [TBL] [Abstract][Full Text] [Related]
10. A BCR-JAK2 fusion gene from ins(22;9)(q11;p13p24) in a patient with atypical chronic myeloid leukemia. Xu Y; Yin J; Pan J; Wu C; Wang Q; Yao H; Wu D; Chen S; Sun A Leuk Lymphoma; 2013 Oct; 54(10):2322-4. PubMed ID: 23432689 [No Abstract] [Full Text] [Related]
11. Cooperation between pathologists and clinicians allows a better diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms. Gianelli U; Iurlo A; Cattaneo D; Lambertenghi-Deliliers G Expert Rev Hematol; 2014 Apr; 7(2):255-64. PubMed ID: 24524231 [TBL] [Abstract][Full Text] [Related]
13. The incidence of JAK2 V617F mutation in bcr/abl-negative chronic myeloproliferative disorders: assessment by two different detection methods. Lucia E; Martino B; Mammi C; Vigna E; Mazzone C; Gentile M; Qualtieri G; Bisconte MG; Naccarato M; Gentile C; Laganà C; Romeo F; Neri A; Nobile F; Morabito F Leuk Lymphoma; 2008 Oct; 49(10):1907-15. PubMed ID: 18720212 [TBL] [Abstract][Full Text] [Related]
14. Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden. Larsen TS; Pallisgaard N; de Stricker K; Møller MB; Hasselbalch HC Hematology; 2009 Feb; 14(1):11-5. PubMed ID: 19154659 [TBL] [Abstract][Full Text] [Related]
15. Accurate quantitation of JAK2 V617F allele burden by array-based digital PCR. Kinz E; Leiherer A; Lang AH; Drexel H; Muendlein A Int J Lab Hematol; 2015 Apr; 37(2):217-24. PubMed ID: 24963593 [TBL] [Abstract][Full Text] [Related]
16. JAK2 V617F mutation prevalence in myeloproliferative neoplasms in Pernambuco, Brazil. da Silva RR; Domingues Hatzlhofer BL; Machado CG; Lima AS; de Albuquerque DM; dos Santos MN; Fertrin KY; Costa FF; Araújo Ada S; Bezerra MA Genet Test Mol Biomarkers; 2012 Jul; 16(7):802-5. PubMed ID: 22304488 [TBL] [Abstract][Full Text] [Related]
17. Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study. Vannucchi AM; Verstovsek S; Guglielmelli P; Griesshammer M; Burn TC; Naim A; Paranagama D; Marker M; Gadbaw B; Kiladjian JJ Ann Hematol; 2017 Jul; 96(7):1113-1120. PubMed ID: 28456851 [TBL] [Abstract][Full Text] [Related]
18. Clinical course and molecular features in 21 patients with atypical chronic myeloid leukemia. Koldehoff M; Steckel NK; Hegerfeldt Y; Ditschkowski M; Beelen DW; Elmaagacli AH Int J Lab Hematol; 2012 Feb; 34(1):e3-5. PubMed ID: 21707937 [No Abstract] [Full Text] [Related]
19. Rapid identification of heterozygous or homozygous JAK2(V617F) mutations in myeloproliferative neoplasms using melting curve analysis. Ho CL; Wu YY; Hung HM; Chang PY; Kao WY; Chen YC; Chao TY J Formos Med Assoc; 2012 Jan; 111(1):34-40. PubMed ID: 22333011 [TBL] [Abstract][Full Text] [Related]
20. Mutational analysis in BCR-ABL-negative classic myeloproliferative neoplasms: impact on prognosis and therapeutic choices. Tefferi A Leuk Lymphoma; 2010 Apr; 51(4):576-82. PubMed ID: 20214447 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]